TG Therapeutics, Inc. cash flow statement TGTX

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, TG Therapeutics, Inc. used $24.8 million of cash from operations, up 38.9% from the year before. It spent $214,000 on capital expenditures. Free cash flow was negative, at -$25.0 million. The company returned $91.2 million in share buybacks to shareholders.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.

Line	FY 2026 Jun 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2012 Dec 31, 2012	FY 2011 Dec 31, 2011
Operating
Depreciation and amortization	0 +200.0%	0 -13.2%	0 -67.8%	0 -30.4%	0 +7.4%	0 +78.5%	0 +58.0%	0 +13.6%	0	—
Stock-based compensation	81 +47.4%	65 +52.0%	43 +12.1%	38 -15.1%	45 -27.1%	61 -23.7%	80 +608.3%	11 -12.0%	3 +3856.6%	0
Operating cash flow	18 +130.2%	-25 +38.9%	-41 -29.0%	-31 +82.2%	-176 +40.4%	-296 -37.8%	-215 -61.5%	-133	-5 -5892.3%	-0
Investing
Capital expenditures	0	0 +375.6%	0	0 -100.0%	0 -96.5%	0 +12.3%	0 +172.5%	0 +45.6%	0	—
Investing cash flow	22 +309.0%	14 +1431.9%	-1 +98.0%	-51 -153.1%	-20 -5928.0%	-0 +98.6%	-25 -3313.6%	-1	-0 -113.5%	0
Financing
Debt repaid	—	—	—	—	—	—	—	—	0	—
Short-term debt repaid	—	—	—	—	—	—	—	—	0	—
Stock buybacks	178	91 +941.6%	9	—	—	—	—	—	—	—
Financing cash flow	314 +170.8%	-90 -169.8%	129 +76.8%	73 +18694.6%	-0 -100.9%	41 -93.9%	680 +232.9%	204	12 +21.1%	10
Change in cash
Net change in cash	353 +664.5%	-101 -215.8%	87 +1029.3%	-9 +95.2%	-197 +22.8%	-255 -157.7%	441 +523.6%	71	—	—
Free cash flow	17	-25 +38.4%	-41 -29.1%	-31 +82.2%	-176 +40.5%	-296 -37.8%	-215 -61.6%	-133	-5	—
Per share
Free cash flow per share	0.11	-0.15 +38.8%	-0.25 -19.6%	-0.21 +83.7%	-1.30	—	—	—	—	—
Shareholder returns
Returned to shareholders	178	91	9	—	—	—	—	—	—	—
Share of free cash flow	1,025.22%	—	—	—	—	—	—	—	—	—
Ratios
Free cash flow margin	2.17%	-4.05%	-12.33%	-13.44%	-6,326.18%	-4,425.70%	-141,357.89%	-87,458.55%	—	—
Capital expenditures to revenue	0.06%	0.03%	0.01%	0.00%	0.50%	5.99%	234.87%	86.18%	—	—
Stock-based compensation to revenue	10.15%	10.49%	12.93%	16.23%	1,603.66%	916.04%	52,821.71%	7,457.24%	—	—
Cash conversion	0.04x	-0.06x	-1.73x	-2.48x	—	—	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: TGTX (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: New York, NY
SEC filer status: Large accelerated filer
SEC CIK: 1001316
Former names: MANHATTAN PHARMACEUTICALS INC (until Apr 27, 2012); ATLANTIC TECHNOLOGY VENTURES INC (until Mar 10, 2003); ATLANTIC PHARMACEUTICALS INC (until Feb 4, 2000)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.